Drug Profile
MV 012 968
Alternative Names: MV-012-968; OE4 (RSV-A2-dNS1-dNS2-DSH-dGm)-Gsnull-line19F; Respiratory syncytial virus vaccine - Meissa Vaccine; RSV vaccine - Meissa VaccineLatest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Emory University
- Developer Meissa Vaccines
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 08 Aug 2023 Safety and efficacy data from a phase I trial in Respiratory syncytial virus infections (prevention) released by Meissa Vaccines
- 08 Aug 2023 Meissa plans a phase II/III trial for Respiratory syncytial virus infections (prevention) in next year
- 28 Jul 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention) in USA (Intranasal, Drops)